nodes	percent_of_prediction	percent_of_DWPC	metapath
Crizotinib—PRKD3—pancreas—gallbladder cancer	0.00558	0.0159	CbGeAlD
Crizotinib—MET—epithelium—gallbladder cancer	0.00542	0.0155	CbGeAlD
Crizotinib—MAPK7—pancreas—gallbladder cancer	0.00515	0.0147	CbGeAlD
Crizotinib—MET—pancreas—gallbladder cancer	0.00483	0.0138	CbGeAlD
Crizotinib—ACVR1B—pancreas—gallbladder cancer	0.00446	0.0127	CbGeAlD
Crizotinib—BMPR1B—epithelium—gallbladder cancer	0.00434	0.0124	CbGeAlD
Crizotinib—IKBKE—lymph node—gallbladder cancer	0.00433	0.0124	CbGeAlD
Crizotinib—IGF1R—epithelium—gallbladder cancer	0.00426	0.0122	CbGeAlD
Crizotinib—TIE1—epithelium—gallbladder cancer	0.00414	0.0118	CbGeAlD
Crizotinib—NEK9—liver—gallbladder cancer	0.00405	0.0116	CbGeAlD
Crizotinib—IGF1R—pancreas—gallbladder cancer	0.00379	0.0108	CbGeAlD
Crizotinib—SIK2—liver—gallbladder cancer	0.00364	0.0104	CbGeAlD
Crizotinib—PRKD3—liver—gallbladder cancer	0.00355	0.0101	CbGeAlD
Crizotinib—RIPK2—epithelium—gallbladder cancer	0.0034	0.00973	CbGeAlD
Crizotinib—CASK—liver—gallbladder cancer	0.00339	0.00968	CbGeAlD
Crizotinib—NUAK2—pancreas—gallbladder cancer	0.00338	0.00966	CbGeAlD
Crizotinib—ACVR1—pancreas—gallbladder cancer	0.00336	0.00959	CbGeAlD
Crizotinib—STK35—pancreas—gallbladder cancer	0.00329	0.0094	CbGeAlD
Crizotinib—FES—liver—gallbladder cancer	0.00325	0.00928	CbGeAlD
Crizotinib—PTK2—epithelium—gallbladder cancer	0.00316	0.00903	CbGeAlD
Crizotinib—NEK9—lymph node—gallbladder cancer	0.00311	0.00888	CbGeAlD
Crizotinib—MET—liver—gallbladder cancer	0.00307	0.00877	CbGeAlD
Crizotinib—RPS6KB1—epithelium—gallbladder cancer	0.00304	0.00869	CbGeAlD
Crizotinib—CDK7—liver—gallbladder cancer	0.00297	0.00849	CbGeAlD
Crizotinib—TAOK2—liver—gallbladder cancer	0.00295	0.00842	CbGeAlD
Crizotinib—EPHB4—epithelium—gallbladder cancer	0.00288	0.00822	CbGeAlD
Crizotinib—JAK2—epithelium—gallbladder cancer	0.00286	0.00816	CbGeAlD
Crizotinib—ACVR1B—liver—gallbladder cancer	0.00284	0.00811	CbGeAlD
Crizotinib—PRKD1—lymph node—gallbladder cancer	0.00283	0.00809	CbGeAlD
Crizotinib—EPHA2—epithelium—gallbladder cancer	0.00282	0.00806	CbGeAlD
Crizotinib—PTK2—pancreas—gallbladder cancer	0.00281	0.00804	CbGeAlD
Crizotinib—TBK1—pancreas—gallbladder cancer	0.00281	0.00804	CbGeAlD
Crizotinib—TYK2—pancreas—gallbladder cancer	0.0028	0.00799	CbGeAlD
Crizotinib—LIMK1—lymph node—gallbladder cancer	0.00279	0.00798	CbGeAlD
Crizotinib—IRAK1—pancreas—gallbladder cancer	0.00276	0.00789	CbGeAlD
Crizotinib—TEK—epithelium—gallbladder cancer	0.00275	0.00787	CbGeAlD
Crizotinib—PRKD3—lymph node—gallbladder cancer	0.00272	0.00778	CbGeAlD
Crizotinib—RPS6KB1—pancreas—gallbladder cancer	0.00271	0.00774	CbGeAlD
Crizotinib—STK4—liver—gallbladder cancer	0.00266	0.00759	CbGeAlD
Crizotinib—DSTYK—lymph node—gallbladder cancer	0.00266	0.00759	CbGeAlD
Crizotinib—BLK—lymph node—gallbladder cancer	0.00263	0.0075	CbGeAlD
Crizotinib—LTK—lymph node—gallbladder cancer	0.0026	0.00742	CbGeAlD
Crizotinib—CASK—lymph node—gallbladder cancer	0.0026	0.00742	CbGeAlD
Crizotinib—SLK—pancreas—gallbladder cancer	0.00258	0.00737	CbGeAlD
Crizotinib—EPHB4—pancreas—gallbladder cancer	0.00256	0.00732	CbGeAlD
Crizotinib—MAPK7—lymph node—gallbladder cancer	0.00251	0.00719	CbGeAlD
Crizotinib—TXK—lymph node—gallbladder cancer	0.00251	0.00719	CbGeAlD
Crizotinib—EPHA2—pancreas—gallbladder cancer	0.00251	0.00718	CbGeAlD
Crizotinib—FER—liver—gallbladder cancer	0.00251	0.00718	CbGeAlD
Crizotinib—LYN—liver—gallbladder cancer	0.0025	0.00714	CbGeAlD
Crizotinib—FES—lymph node—gallbladder cancer	0.00249	0.00711	CbGeAlD
Crizotinib—TNK1—liver—gallbladder cancer	0.00249	0.0071	CbGeAlD
Crizotinib—TEK—pancreas—gallbladder cancer	0.00245	0.00701	CbGeAlD
Crizotinib—MAP4K5—pancreas—gallbladder cancer	0.00245	0.00701	CbGeAlD
Crizotinib—SRC—epithelium—gallbladder cancer	0.00245	0.00699	CbGeAlD
Crizotinib—IGF1R—liver—gallbladder cancer	0.00241	0.0069	CbGeAlD
Crizotinib—TNK2—liver—gallbladder cancer	0.00241	0.0069	CbGeAlD
Crizotinib—MAP4K2—liver—gallbladder cancer	0.00238	0.0068	CbGeAlD
Crizotinib—MET—lymph node—gallbladder cancer	0.00235	0.00673	CbGeAlD
Crizotinib—TIE1—liver—gallbladder cancer	0.00235	0.00671	CbGeAlD
Crizotinib—STK3—liver—gallbladder cancer	0.00235	0.00671	CbGeAlD
Crizotinib—AURKA—liver—gallbladder cancer	0.00229	0.00654	CbGeAlD
Crizotinib—CDK7—lymph node—gallbladder cancer	0.00228	0.00651	CbGeAlD
Crizotinib—TESK1—liver—gallbladder cancer	0.00227	0.00648	CbGeAlD
Crizotinib—YES1—pancreas—gallbladder cancer	0.00226	0.00647	CbGeAlD
Crizotinib—TAOK2—lymph node—gallbladder cancer	0.00226	0.00646	CbGeAlD
Crizotinib—TAOK3—pancreas—gallbladder cancer	0.00224	0.00639	CbGeAlD
Crizotinib—MERTK—liver—gallbladder cancer	0.00221	0.00631	CbGeAlD
Crizotinib—SRC—pancreas—gallbladder cancer	0.00218	0.00623	CbGeAlD
Crizotinib—EPHA3—lymph node—gallbladder cancer	0.00218	0.00622	CbGeAlD
Crizotinib—ACVR1B—lymph node—gallbladder cancer	0.00218	0.00622	CbGeAlD
Crizotinib—LIMK2—liver—gallbladder cancer	0.00216	0.00617	CbGeAlD
Crizotinib—NUAK2—liver—gallbladder cancer	0.00215	0.00615	CbGeAlD
Crizotinib—MAP3K12—liver—gallbladder cancer	0.00214	0.0061	CbGeAlD
Crizotinib—FLT3—liver—gallbladder cancer	0.00214	0.0061	CbGeAlD
Crizotinib—ACVR1—liver—gallbladder cancer	0.00214	0.0061	CbGeAlD
Crizotinib—STK35—liver—gallbladder cancer	0.00209	0.00598	CbGeAlD
Crizotinib—JAK3—lymph node—gallbladder cancer	0.00208	0.00593	CbGeAlD
Crizotinib—DCLK1—lymph node—gallbladder cancer	0.00206	0.0059	CbGeAlD
Crizotinib—PLK4—lymph node—gallbladder cancer	0.00205	0.00586	CbGeAlD
Crizotinib—ABL2—liver—gallbladder cancer	0.00204	0.00583	CbGeAlD
Crizotinib—STK4—lymph node—gallbladder cancer	0.00204	0.00582	CbGeAlD
Crizotinib—BMP2K—liver—gallbladder cancer	0.00201	0.00576	CbGeAlD
Crizotinib—PTK2B—liver—gallbladder cancer	0.00194	0.00556	CbGeAlD
Crizotinib—RIPK2—liver—gallbladder cancer	0.00193	0.00551	CbGeAlD
Crizotinib—ALK—lymph node—gallbladder cancer	0.00193	0.0055	CbGeAlD
Crizotinib—FER—lymph node—gallbladder cancer	0.00193	0.0055	CbGeAlD
Crizotinib—TNK1—lymph node—gallbladder cancer	0.00191	0.00545	CbGeAlD
Crizotinib—MAP4K1—lymph node—gallbladder cancer	0.00189	0.00539	CbGeAlD
Crizotinib—BMPR1B—lymph node—gallbladder cancer	0.00189	0.00539	CbGeAlD
Crizotinib—IGF1R—lymph node—gallbladder cancer	0.00185	0.00529	CbGeAlD
Crizotinib—TNK2—lymph node—gallbladder cancer	0.00185	0.00529	CbGeAlD
Crizotinib—MAP3K2—liver—gallbladder cancer	0.00183	0.00523	CbGeAlD
Crizotinib—MAP4K2—lymph node—gallbladder cancer	0.00182	0.00521	CbGeAlD
Crizotinib—STK3—lymph node—gallbladder cancer	0.0018	0.00514	CbGeAlD
Crizotinib—TIE1—lymph node—gallbladder cancer	0.0018	0.00514	CbGeAlD
Crizotinib—PTK2—liver—gallbladder cancer	0.00179	0.00512	CbGeAlD
Crizotinib—TBK1—liver—gallbladder cancer	0.00179	0.00512	CbGeAlD
Crizotinib—TYK2—liver—gallbladder cancer	0.00178	0.00508	CbGeAlD
Crizotinib—IRAK1—liver—gallbladder cancer	0.00176	0.00502	CbGeAlD
Crizotinib—AURKA—lymph node—gallbladder cancer	0.00175	0.00501	CbGeAlD
Crizotinib—TESK1—lymph node—gallbladder cancer	0.00174	0.00497	CbGeAlD
Crizotinib—RPS6KB1—liver—gallbladder cancer	0.00172	0.00492	CbGeAlD
Crizotinib—LCK—liver—gallbladder cancer	0.00171	0.00489	CbGeAlD
Crizotinib—FGR—liver—gallbladder cancer	0.00171	0.00489	CbGeAlD
Crizotinib—AXL—liver—gallbladder cancer	0.00171	0.00487	CbGeAlD
Crizotinib—MERTK—lymph node—gallbladder cancer	0.00169	0.00484	CbGeAlD
Crizotinib—LIMK2—lymph node—gallbladder cancer	0.00165	0.00473	CbGeAlD
Crizotinib—NUAK2—lymph node—gallbladder cancer	0.00165	0.00471	CbGeAlD
Crizotinib—SLK—liver—gallbladder cancer	0.00164	0.00469	CbGeAlD
Crizotinib—FLT3—lymph node—gallbladder cancer	0.00164	0.00468	CbGeAlD
Crizotinib—MAP3K12—lymph node—gallbladder cancer	0.00164	0.00468	CbGeAlD
Crizotinib—ACVR1—lymph node—gallbladder cancer	0.00164	0.00468	CbGeAlD
Crizotinib—EPHB4—liver—gallbladder cancer	0.00163	0.00466	CbGeAlD
Crizotinib—JAK2—liver—gallbladder cancer	0.00162	0.00463	CbGeAlD
Crizotinib—STK35—lymph node—gallbladder cancer	0.0016	0.00458	CbGeAlD
Crizotinib—EPHA2—liver—gallbladder cancer	0.0016	0.00457	CbGeAlD
Crizotinib—ABL2—lymph node—gallbladder cancer	0.00156	0.00447	CbGeAlD
Crizotinib—TEK—liver—gallbladder cancer	0.00156	0.00446	CbGeAlD
Crizotinib—MAP3K3—liver—gallbladder cancer	0.00156	0.00446	CbGeAlD
Crizotinib—MAP4K5—liver—gallbladder cancer	0.00156	0.00446	CbGeAlD
Crizotinib—ABL1—pancreas—gallbladder cancer	0.00155	0.00442	CbGeAlD
Crizotinib—BMP2K—lymph node—gallbladder cancer	0.00154	0.00441	CbGeAlD
Crizotinib—PTK2B—lymph node—gallbladder cancer	0.00149	0.00426	CbGeAlD
Crizotinib—RIPK2—lymph node—gallbladder cancer	0.00148	0.00423	CbGeAlD
Crizotinib—YES1—liver—gallbladder cancer	0.00144	0.00412	CbGeAlD
Crizotinib—EPHA4—lymph node—gallbladder cancer	0.00143	0.00409	CbGeAlD
Crizotinib—STK10—liver—gallbladder cancer	0.00143	0.00408	CbGeAlD
Crizotinib—TAOK3—liver—gallbladder cancer	0.00142	0.00406	CbGeAlD
Crizotinib—MAP3K2—lymph node—gallbladder cancer	0.0014	0.00401	CbGeAlD
Crizotinib—SRC—liver—gallbladder cancer	0.00139	0.00396	CbGeAlD
Crizotinib—TBK1—lymph node—gallbladder cancer	0.00137	0.00392	CbGeAlD
Crizotinib—PTK2—lymph node—gallbladder cancer	0.00137	0.00392	CbGeAlD
Crizotinib—TYK2—lymph node—gallbladder cancer	0.00136	0.0039	CbGeAlD
Crizotinib—IRAK1—lymph node—gallbladder cancer	0.00135	0.00385	CbGeAlD
Crizotinib—RPS6KB1—lymph node—gallbladder cancer	0.00132	0.00378	CbGeAlD
Crizotinib—LCK—lymph node—gallbladder cancer	0.00131	0.00375	CbGeAlD
Crizotinib—FGR—lymph node—gallbladder cancer	0.00131	0.00375	CbGeAlD
Crizotinib—AXL—lymph node—gallbladder cancer	0.00131	0.00374	CbGeAlD
Crizotinib—SLK—lymph node—gallbladder cancer	0.00126	0.0036	CbGeAlD
Crizotinib—EPHB4—lymph node—gallbladder cancer	0.00125	0.00357	CbGeAlD
Crizotinib—CSF1R—liver—gallbladder cancer	0.00124	0.00356	CbGeAlD
Crizotinib—JAK2—lymph node—gallbladder cancer	0.00124	0.00355	CbGeAlD
Crizotinib—EPHA2—lymph node—gallbladder cancer	0.00123	0.0035	CbGeAlD
Crizotinib—MAP4K5—lymph node—gallbladder cancer	0.0012	0.00342	CbGeAlD
Crizotinib—MAP3K3—lymph node—gallbladder cancer	0.0012	0.00342	CbGeAlD
Crizotinib—TEK—lymph node—gallbladder cancer	0.0012	0.00342	CbGeAlD
Crizotinib—EPHB6—lymph node—gallbladder cancer	0.00114	0.00327	CbGeAlD
Crizotinib—YES1—lymph node—gallbladder cancer	0.0011	0.00316	CbGeAlD
Crizotinib—STK10—lymph node—gallbladder cancer	0.00109	0.00313	CbGeAlD
Crizotinib—TAOK3—lymph node—gallbladder cancer	0.00109	0.00312	CbGeAlD
Crizotinib—SRC—lymph node—gallbladder cancer	0.00106	0.00304	CbGeAlD
Crizotinib—ABL1—liver—gallbladder cancer	0.000983	0.00281	CbGeAlD
Crizotinib—CSF1R—lymph node—gallbladder cancer	0.000954	0.00273	CbGeAlD
Crizotinib—CYP3A5—pancreas—gallbladder cancer	0.000905	0.00259	CbGeAlD
Crizotinib—ABL1—lymph node—gallbladder cancer	0.000754	0.00216	CbGeAlD
Crizotinib—CYP3A5—liver—gallbladder cancer	0.000576	0.00165	CbGeAlD
Crizotinib—ABCB1—epithelium—gallbladder cancer	0.00054	0.00154	CbGeAlD
Crizotinib—ABCB1—pancreas—gallbladder cancer	0.000481	0.00137	CbGeAlD
Crizotinib—CYP3A4—liver—gallbladder cancer	0.000432	0.00123	CbGeAlD
Crizotinib—ABCB1—liver—gallbladder cancer	0.000306	0.000874	CbGeAlD
Crizotinib—ABCB1—lymph node—gallbladder cancer	0.000234	0.00067	CbGeAlD
Crizotinib—JAK2—Innate Immune System—NRAS—gallbladder cancer	3.9e-05	6e-05	CbGpPWpGaD
Crizotinib—SRC—Signaling by NGF—HRAS—gallbladder cancer	3.88e-05	5.97e-05	CbGpPWpGaD
Crizotinib—IRAK1—Innate Immune System—HRAS—gallbladder cancer	3.88e-05	5.96e-05	CbGpPWpGaD
Crizotinib—LCK—Disease—ERBB3—gallbladder cancer	3.85e-05	5.92e-05	CbGpPWpGaD
Crizotinib—IGF1R—Signaling Pathways—EGFR—gallbladder cancer	3.84e-05	5.91e-05	CbGpPWpGaD
Crizotinib—RIPK2—Immune System—EGFR—gallbladder cancer	3.83e-05	5.89e-05	CbGpPWpGaD
Crizotinib—TBK1—Immune System—HRAS—gallbladder cancer	3.82e-05	5.87e-05	CbGpPWpGaD
Crizotinib—SRC—Adaptive Immune System—ERBB2—gallbladder cancer	3.82e-05	5.87e-05	CbGpPWpGaD
Crizotinib—LYN—Signaling Pathways—ERBB4—gallbladder cancer	3.8e-05	5.85e-05	CbGpPWpGaD
Crizotinib—JAK2—Developmental Biology—KRAS—gallbladder cancer	3.8e-05	5.85e-05	CbGpPWpGaD
Crizotinib—LYN—Innate Immune System—EGFR—gallbladder cancer	3.8e-05	5.84e-05	CbGpPWpGaD
Crizotinib—LCK—Hemostasis—NRAS—gallbladder cancer	3.79e-05	5.84e-05	CbGpPWpGaD
Crizotinib—ABL1—Innate Immune System—EGFR—gallbladder cancer	3.78e-05	5.81e-05	CbGpPWpGaD
Crizotinib—JAK3—Signaling by GPCR—HRAS—gallbladder cancer	3.78e-05	5.81e-05	CbGpPWpGaD
Crizotinib—PTK2B—Immune System—EGFR—gallbladder cancer	3.78e-05	5.81e-05	CbGpPWpGaD
Crizotinib—TYK2—Innate Immune System—HRAS—gallbladder cancer	3.76e-05	5.79e-05	CbGpPWpGaD
Crizotinib—MAPK7—Signaling Pathways—EGFR—gallbladder cancer	3.76e-05	5.79e-05	CbGpPWpGaD
Crizotinib—ABCB1—Integrated Pancreatic Cancer Pathway—KRAS—gallbladder cancer	3.73e-05	5.73e-05	CbGpPWpGaD
Crizotinib—JAK2—Hemostasis—KRAS—gallbladder cancer	3.73e-05	5.73e-05	CbGpPWpGaD
Crizotinib—CDK7—Disease—EGFR—gallbladder cancer	3.71e-05	5.7e-05	CbGpPWpGaD
Crizotinib—SRC—Immune System—ERBB3—gallbladder cancer	3.69e-05	5.68e-05	CbGpPWpGaD
Crizotinib—BLK—Immune System—EGFR—gallbladder cancer	3.69e-05	5.67e-05	CbGpPWpGaD
Crizotinib—FGR—Immune System—EGFR—gallbladder cancer	3.67e-05	5.65e-05	CbGpPWpGaD
Crizotinib—MAP3K3—Immune System—HRAS—gallbladder cancer	3.66e-05	5.63e-05	CbGpPWpGaD
Crizotinib—LYN—Adaptive Immune System—EGFR—gallbladder cancer	3.65e-05	5.61e-05	CbGpPWpGaD
Crizotinib—TYK2—Disease—ERBB2—gallbladder cancer	3.64e-05	5.59e-05	CbGpPWpGaD
Crizotinib—IGF1R—Signaling Pathways—KRAS—gallbladder cancer	3.63e-05	5.59e-05	CbGpPWpGaD
Crizotinib—RIPK2—Immune System—KRAS—gallbladder cancer	3.62e-05	5.57e-05	CbGpPWpGaD
Crizotinib—LYN—Innate Immune System—KRAS—gallbladder cancer	3.59e-05	5.52e-05	CbGpPWpGaD
Crizotinib—RIPK2—Signaling Pathways—ERBB2—gallbladder cancer	3.57e-05	5.5e-05	CbGpPWpGaD
Crizotinib—ABL1—Innate Immune System—KRAS—gallbladder cancer	3.57e-05	5.49e-05	CbGpPWpGaD
Crizotinib—FES—Signaling Pathways—TP53—gallbladder cancer	3.57e-05	5.49e-05	CbGpPWpGaD
Crizotinib—PTK2B—Immune System—KRAS—gallbladder cancer	3.57e-05	5.49e-05	CbGpPWpGaD
Crizotinib—JAK2—Signaling Pathways—ERBB4—gallbladder cancer	3.56e-05	5.48e-05	CbGpPWpGaD
Crizotinib—MAPK7—Signaling Pathways—KRAS—gallbladder cancer	3.55e-05	5.47e-05	CbGpPWpGaD
Crizotinib—JAK2—Innate Immune System—EGFR—gallbladder cancer	3.55e-05	5.46e-05	CbGpPWpGaD
Crizotinib—LYN—Hemostasis—TP53—gallbladder cancer	3.54e-05	5.45e-05	CbGpPWpGaD
Crizotinib—ABL1—Hemostasis—TP53—gallbladder cancer	3.52e-05	5.42e-05	CbGpPWpGaD
Crizotinib—PTK2B—Signaling Pathways—ERBB2—gallbladder cancer	3.52e-05	5.42e-05	CbGpPWpGaD
Crizotinib—SRC—Axon guidance—HRAS—gallbladder cancer	3.51e-05	5.4e-05	CbGpPWpGaD
Crizotinib—CDK7—Disease—KRAS—gallbladder cancer	3.5e-05	5.39e-05	CbGpPWpGaD
Crizotinib—BLK—Immune System—KRAS—gallbladder cancer	3.48e-05	5.36e-05	CbGpPWpGaD
Crizotinib—FGR—Immune System—KRAS—gallbladder cancer	3.47e-05	5.34e-05	CbGpPWpGaD
Crizotinib—JAK3—Immune System—HRAS—gallbladder cancer	3.45e-05	5.31e-05	CbGpPWpGaD
Crizotinib—LYN—Developmental Biology—HRAS—gallbladder cancer	3.45e-05	5.31e-05	CbGpPWpGaD
Crizotinib—LYN—Adaptive Immune System—KRAS—gallbladder cancer	3.44e-05	5.3e-05	CbGpPWpGaD
Crizotinib—ABL1—Developmental Biology—HRAS—gallbladder cancer	3.44e-05	5.28e-05	CbGpPWpGaD
Crizotinib—SRC—Developmental Biology—NRAS—gallbladder cancer	3.42e-05	5.27e-05	CbGpPWpGaD
Crizotinib—LCK—Innate Immune System—NRAS—gallbladder cancer	3.42e-05	5.25e-05	CbGpPWpGaD
Crizotinib—FES—Signaling Pathways—HRAS—gallbladder cancer	3.41e-05	5.25e-05	CbGpPWpGaD
Crizotinib—SRC—Disease—ERBB3—gallbladder cancer	3.41e-05	5.24e-05	CbGpPWpGaD
Crizotinib—LYN—Hemostasis—HRAS—gallbladder cancer	3.39e-05	5.21e-05	CbGpPWpGaD
Crizotinib—NTRK1—Signaling Pathways—ERBB2—gallbladder cancer	3.37e-05	5.19e-05	CbGpPWpGaD
Crizotinib—ABL1—Hemostasis—HRAS—gallbladder cancer	3.37e-05	5.18e-05	CbGpPWpGaD
Crizotinib—SRC—Hemostasis—NRAS—gallbladder cancer	3.36e-05	5.17e-05	CbGpPWpGaD
Crizotinib—JAK2—Innate Immune System—KRAS—gallbladder cancer	3.36e-05	5.16e-05	CbGpPWpGaD
Crizotinib—ABCB1—Integrated Pancreatic Cancer Pathway—TP53—gallbladder cancer	3.31e-05	5.1e-05	CbGpPWpGaD
Crizotinib—JAK2—Hemostasis—TP53—gallbladder cancer	3.31e-05	5.1e-05	CbGpPWpGaD
Crizotinib—PTK2—Immune System—NRAS—gallbladder cancer	3.3e-05	5.08e-05	CbGpPWpGaD
Crizotinib—LYN—Signaling Pathways—ERBB3—gallbladder cancer	3.29e-05	5.06e-05	CbGpPWpGaD
Crizotinib—LYN—Immune System—BCL2—gallbladder cancer	3.28e-05	5.05e-05	CbGpPWpGaD
Crizotinib—TYK2—Signaling by GPCR—NRAS—gallbladder cancer	3.28e-05	5.04e-05	CbGpPWpGaD
Crizotinib—LCK—Adaptive Immune System—NRAS—gallbladder cancer	3.28e-05	5.04e-05	CbGpPWpGaD
Crizotinib—RPS6KB1—Signaling Pathways—ERBB2—gallbladder cancer	3.27e-05	5.03e-05	CbGpPWpGaD
Crizotinib—ABL1—Immune System—BCL2—gallbladder cancer	3.27e-05	5.03e-05	CbGpPWpGaD
Crizotinib—LCK—Hemostasis—KRAS—gallbladder cancer	3.26e-05	5.02e-05	CbGpPWpGaD
Crizotinib—YES1—Immune System—NRAS—gallbladder cancer	3.25e-05	5.01e-05	CbGpPWpGaD
Crizotinib—JAK2—Developmental Biology—HRAS—gallbladder cancer	3.23e-05	4.97e-05	CbGpPWpGaD
Crizotinib—IGF1R—Signaling Pathways—TP53—gallbladder cancer	3.23e-05	4.97e-05	CbGpPWpGaD
Crizotinib—LYN—Immune System—ERBB2—gallbladder cancer	3.19e-05	4.91e-05	CbGpPWpGaD
Crizotinib—ABL1—Immune System—ERBB2—gallbladder cancer	3.17e-05	4.88e-05	CbGpPWpGaD
Crizotinib—JAK2—Hemostasis—HRAS—gallbladder cancer	3.17e-05	4.87e-05	CbGpPWpGaD
Crizotinib—MAPK7—Signaling Pathways—TP53—gallbladder cancer	3.16e-05	4.86e-05	CbGpPWpGaD
Crizotinib—SRC—Developmental Biology—EGFR—gallbladder cancer	3.12e-05	4.8e-05	CbGpPWpGaD
Crizotinib—LCK—Signaling Pathways—ERBB4—gallbladder cancer	3.12e-05	4.8e-05	CbGpPWpGaD
Crizotinib—LCK—Innate Immune System—EGFR—gallbladder cancer	3.11e-05	4.79e-05	CbGpPWpGaD
Crizotinib—IGF1R—Signaling Pathways—HRAS—gallbladder cancer	3.09e-05	4.75e-05	CbGpPWpGaD
Crizotinib—IRAK1—Immune System—NRAS—gallbladder cancer	3.09e-05	4.75e-05	CbGpPWpGaD
Crizotinib—JAK2—Signaling Pathways—ERBB3—gallbladder cancer	3.08e-05	4.73e-05	CbGpPWpGaD
Crizotinib—RIPK2—Immune System—HRAS—gallbladder cancer	3.08e-05	4.73e-05	CbGpPWpGaD
Crizotinib—JAK2—Immune System—BCL2—gallbladder cancer	3.07e-05	4.73e-05	CbGpPWpGaD
Crizotinib—JAK3—Signaling Pathways—NRAS—gallbladder cancer	3.05e-05	4.69e-05	CbGpPWpGaD
Crizotinib—LYN—Innate Immune System—HRAS—gallbladder cancer	3.05e-05	4.69e-05	CbGpPWpGaD
Crizotinib—ABL1—Innate Immune System—HRAS—gallbladder cancer	3.03e-05	4.67e-05	CbGpPWpGaD
Crizotinib—PTK2B—Immune System—HRAS—gallbladder cancer	3.03e-05	4.66e-05	CbGpPWpGaD
Crizotinib—SRC—Innate Immune System—NRAS—gallbladder cancer	3.02e-05	4.65e-05	CbGpPWpGaD
Crizotinib—MAPK7—Signaling Pathways—HRAS—gallbladder cancer	3.02e-05	4.65e-05	CbGpPWpGaD
Crizotinib—PTK2—Immune System—EGFR—gallbladder cancer	3.01e-05	4.62e-05	CbGpPWpGaD
Crizotinib—TYK2—Immune System—NRAS—gallbladder cancer	3e-05	4.61e-05	CbGpPWpGaD
Crizotinib—TYK2—Signaling by GPCR—EGFR—gallbladder cancer	2.99e-05	4.6e-05	CbGpPWpGaD
Crizotinib—LCK—Adaptive Immune System—EGFR—gallbladder cancer	2.99e-05	4.6e-05	CbGpPWpGaD
Crizotinib—JAK2—Immune System—ERBB2—gallbladder cancer	2.99e-05	4.59e-05	CbGpPWpGaD
Crizotinib—CDK7—Disease—HRAS—gallbladder cancer	2.98e-05	4.58e-05	CbGpPWpGaD
Crizotinib—YES1—Immune System—EGFR—gallbladder cancer	2.97e-05	4.56e-05	CbGpPWpGaD
Crizotinib—BLK—Immune System—HRAS—gallbladder cancer	2.96e-05	4.55e-05	CbGpPWpGaD
Crizotinib—FGR—Immune System—HRAS—gallbladder cancer	2.95e-05	4.54e-05	CbGpPWpGaD
Crizotinib—SRC—Developmental Biology—KRAS—gallbladder cancer	2.95e-05	4.53e-05	CbGpPWpGaD
Crizotinib—LCK—Innate Immune System—KRAS—gallbladder cancer	2.94e-05	4.52e-05	CbGpPWpGaD
Crizotinib—LYN—Adaptive Immune System—HRAS—gallbladder cancer	2.93e-05	4.5e-05	CbGpPWpGaD
Crizotinib—SRC—Adaptive Immune System—NRAS—gallbladder cancer	2.9e-05	4.47e-05	CbGpPWpGaD
Crizotinib—LCK—Hemostasis—TP53—gallbladder cancer	2.9e-05	4.46e-05	CbGpPWpGaD
Crizotinib—SRC—Hemostasis—KRAS—gallbladder cancer	2.89e-05	4.45e-05	CbGpPWpGaD
Crizotinib—JAK2—Innate Immune System—HRAS—gallbladder cancer	2.85e-05	4.39e-05	CbGpPWpGaD
Crizotinib—PTK2—Immune System—KRAS—gallbladder cancer	2.84e-05	4.37e-05	CbGpPWpGaD
Crizotinib—TYK2—Signaling by GPCR—KRAS—gallbladder cancer	2.82e-05	4.34e-05	CbGpPWpGaD
Crizotinib—LCK—Adaptive Immune System—KRAS—gallbladder cancer	2.82e-05	4.34e-05	CbGpPWpGaD
Crizotinib—IRAK1—Immune System—EGFR—gallbladder cancer	2.81e-05	4.33e-05	CbGpPWpGaD
Crizotinib—PTK2—Signaling Pathways—ERBB2—gallbladder cancer	2.8e-05	4.31e-05	CbGpPWpGaD
Crizotinib—YES1—Immune System—KRAS—gallbladder cancer	2.8e-05	4.31e-05	CbGpPWpGaD
Crizotinib—JAK3—Signaling Pathways—EGFR—gallbladder cancer	2.78e-05	4.28e-05	CbGpPWpGaD
Crizotinib—LCK—Hemostasis—HRAS—gallbladder cancer	2.78e-05	4.27e-05	CbGpPWpGaD
Crizotinib—TYK2—Disease—NRAS—gallbladder cancer	2.77e-05	4.26e-05	CbGpPWpGaD
Crizotinib—YES1—Signaling Pathways—ERBB2—gallbladder cancer	2.77e-05	4.25e-05	CbGpPWpGaD
Crizotinib—SRC—Signaling Pathways—ERBB4—gallbladder cancer	2.76e-05	4.25e-05	CbGpPWpGaD
Crizotinib—JAK2—Disease—ERBB2—gallbladder cancer	2.76e-05	4.24e-05	CbGpPWpGaD
Crizotinib—SRC—Innate Immune System—EGFR—gallbladder cancer	2.75e-05	4.24e-05	CbGpPWpGaD
Crizotinib—TYK2—Immune System—EGFR—gallbladder cancer	2.73e-05	4.2e-05	CbGpPWpGaD
Crizotinib—RIPK2—Signaling Pathways—NRAS—gallbladder cancer	2.72e-05	4.18e-05	CbGpPWpGaD
Crizotinib—LCK—Signaling Pathways—ERBB3—gallbladder cancer	2.7e-05	4.15e-05	CbGpPWpGaD
Crizotinib—LCK—Immune System—BCL2—gallbladder cancer	2.69e-05	4.14e-05	CbGpPWpGaD
Crizotinib—PTK2B—Signaling Pathways—NRAS—gallbladder cancer	2.68e-05	4.12e-05	CbGpPWpGaD
Crizotinib—IRAK1—Immune System—KRAS—gallbladder cancer	2.66e-05	4.09e-05	CbGpPWpGaD
Crizotinib—SRC—Adaptive Immune System—EGFR—gallbladder cancer	2.65e-05	4.07e-05	CbGpPWpGaD
Crizotinib—JAK3—Signaling Pathways—KRAS—gallbladder cancer	2.63e-05	4.04e-05	CbGpPWpGaD
Crizotinib—IRAK1—Signaling Pathways—ERBB2—gallbladder cancer	2.62e-05	4.04e-05	CbGpPWpGaD
Crizotinib—LCK—Immune System—ERBB2—gallbladder cancer	2.61e-05	4.02e-05	CbGpPWpGaD
Crizotinib—SRC—Innate Immune System—KRAS—gallbladder cancer	2.6e-05	4e-05	CbGpPWpGaD
Crizotinib—TYK2—Immune System—KRAS—gallbladder cancer	2.58e-05	3.97e-05	CbGpPWpGaD
Crizotinib—SRC—Hemostasis—TP53—gallbladder cancer	2.57e-05	3.95e-05	CbGpPWpGaD
Crizotinib—NTRK1—Signaling Pathways—NRAS—gallbladder cancer	2.56e-05	3.94e-05	CbGpPWpGaD
Crizotinib—TYK2—Signaling Pathways—ERBB2—gallbladder cancer	2.55e-05	3.92e-05	CbGpPWpGaD
Crizotinib—TYK2—Disease—EGFR—gallbladder cancer	2.52e-05	3.88e-05	CbGpPWpGaD
Crizotinib—SRC—Developmental Biology—HRAS—gallbladder cancer	2.5e-05	3.85e-05	CbGpPWpGaD
Crizotinib—SRC—Adaptive Immune System—KRAS—gallbladder cancer	2.5e-05	3.84e-05	CbGpPWpGaD
Crizotinib—LCK—Innate Immune System—HRAS—gallbladder cancer	2.5e-05	3.84e-05	CbGpPWpGaD
Crizotinib—RPS6KB1—Signaling Pathways—NRAS—gallbladder cancer	2.49e-05	3.83e-05	CbGpPWpGaD
Crizotinib—JAK2—Signaling by GPCR—NRAS—gallbladder cancer	2.49e-05	3.82e-05	CbGpPWpGaD
Crizotinib—RIPK2—Signaling Pathways—EGFR—gallbladder cancer	2.48e-05	3.81e-05	CbGpPWpGaD
Crizotinib—SRC—Hemostasis—HRAS—gallbladder cancer	2.46e-05	3.78e-05	CbGpPWpGaD
Crizotinib—PTK2B—Signaling Pathways—EGFR—gallbladder cancer	2.44e-05	3.76e-05	CbGpPWpGaD
Crizotinib—LYN—Immune System—NRAS—gallbladder cancer	2.43e-05	3.73e-05	CbGpPWpGaD
Crizotinib—ABL1—Immune System—NRAS—gallbladder cancer	2.42e-05	3.72e-05	CbGpPWpGaD
Crizotinib—PTK2—Immune System—HRAS—gallbladder cancer	2.41e-05	3.71e-05	CbGpPWpGaD
Crizotinib—LCK—Disease—ERBB2—gallbladder cancer	2.41e-05	3.71e-05	CbGpPWpGaD
Crizotinib—TYK2—Signaling by GPCR—HRAS—gallbladder cancer	2.4e-05	3.69e-05	CbGpPWpGaD
Crizotinib—LCK—Adaptive Immune System—HRAS—gallbladder cancer	2.4e-05	3.69e-05	CbGpPWpGaD
Crizotinib—SRC—Signaling Pathways—ERBB3—gallbladder cancer	2.39e-05	3.67e-05	CbGpPWpGaD
Crizotinib—SRC—Immune System—BCL2—gallbladder cancer	2.38e-05	3.66e-05	CbGpPWpGaD
Crizotinib—TYK2—Disease—KRAS—gallbladder cancer	2.38e-05	3.66e-05	CbGpPWpGaD
Crizotinib—YES1—Immune System—HRAS—gallbladder cancer	2.38e-05	3.66e-05	CbGpPWpGaD
Crizotinib—RIPK2—Signaling Pathways—KRAS—gallbladder cancer	2.34e-05	3.6e-05	CbGpPWpGaD
Crizotinib—NTRK1—Signaling Pathways—EGFR—gallbladder cancer	2.34e-05	3.59e-05	CbGpPWpGaD
Crizotinib—JAK3—Signaling Pathways—TP53—gallbladder cancer	2.33e-05	3.59e-05	CbGpPWpGaD
Crizotinib—SRC—Immune System—ERBB2—gallbladder cancer	2.31e-05	3.56e-05	CbGpPWpGaD
Crizotinib—PTK2B—Signaling Pathways—KRAS—gallbladder cancer	2.31e-05	3.55e-05	CbGpPWpGaD
Crizotinib—JAK2—Immune System—NRAS—gallbladder cancer	2.27e-05	3.49e-05	CbGpPWpGaD
Crizotinib—RPS6KB1—Signaling Pathways—EGFR—gallbladder cancer	2.27e-05	3.49e-05	CbGpPWpGaD
Crizotinib—JAK2—Signaling by GPCR—EGFR—gallbladder cancer	2.26e-05	3.48e-05	CbGpPWpGaD
Crizotinib—IRAK1—Immune System—HRAS—gallbladder cancer	2.26e-05	3.47e-05	CbGpPWpGaD
Crizotinib—JAK3—Signaling Pathways—HRAS—gallbladder cancer	2.23e-05	3.43e-05	CbGpPWpGaD
Crizotinib—SRC—Innate Immune System—HRAS—gallbladder cancer	2.21e-05	3.4e-05	CbGpPWpGaD
Crizotinib—LYN—Immune System—EGFR—gallbladder cancer	2.21e-05	3.4e-05	CbGpPWpGaD
Crizotinib—NTRK1—Signaling Pathways—KRAS—gallbladder cancer	2.21e-05	3.4e-05	CbGpPWpGaD
Crizotinib—ABL1—Immune System—EGFR—gallbladder cancer	2.2e-05	3.39e-05	CbGpPWpGaD
Crizotinib—TYK2—Immune System—HRAS—gallbladder cancer	2.19e-05	3.37e-05	CbGpPWpGaD
Crizotinib—RPS6KB1—Signaling Pathways—KRAS—gallbladder cancer	2.14e-05	3.29e-05	CbGpPWpGaD
Crizotinib—JAK2—Signaling by GPCR—KRAS—gallbladder cancer	2.14e-05	3.29e-05	CbGpPWpGaD
Crizotinib—SRC—Disease—ERBB2—gallbladder cancer	2.14e-05	3.29e-05	CbGpPWpGaD
Crizotinib—PTK2—Signaling Pathways—NRAS—gallbladder cancer	2.13e-05	3.28e-05	CbGpPWpGaD
Crizotinib—SRC—Adaptive Immune System—HRAS—gallbladder cancer	2.12e-05	3.27e-05	CbGpPWpGaD
Crizotinib—YES1—Signaling Pathways—NRAS—gallbladder cancer	2.1e-05	3.24e-05	CbGpPWpGaD
Crizotinib—JAK2—Disease—NRAS—gallbladder cancer	2.1e-05	3.23e-05	CbGpPWpGaD
Crizotinib—LYN—Immune System—KRAS—gallbladder cancer	2.09e-05	3.21e-05	CbGpPWpGaD
Crizotinib—RIPK2—Signaling Pathways—TP53—gallbladder cancer	2.08e-05	3.2e-05	CbGpPWpGaD
Crizotinib—ABL1—Immune System—KRAS—gallbladder cancer	2.08e-05	3.2e-05	CbGpPWpGaD
Crizotinib—JAK2—Immune System—EGFR—gallbladder cancer	2.07e-05	3.18e-05	CbGpPWpGaD
Crizotinib—LYN—Signaling Pathways—ERBB2—gallbladder cancer	2.06e-05	3.17e-05	CbGpPWpGaD
Crizotinib—PTK2B—Signaling Pathways—TP53—gallbladder cancer	2.05e-05	3.15e-05	CbGpPWpGaD
Crizotinib—TYK2—Disease—HRAS—gallbladder cancer	2.02e-05	3.11e-05	CbGpPWpGaD
Crizotinib—IRAK1—Signaling Pathways—NRAS—gallbladder cancer	2e-05	3.07e-05	CbGpPWpGaD
Crizotinib—RIPK2—Signaling Pathways—HRAS—gallbladder cancer	1.99e-05	3.06e-05	CbGpPWpGaD
Crizotinib—LCK—Immune System—NRAS—gallbladder cancer	1.99e-05	3.06e-05	CbGpPWpGaD
Crizotinib—NTRK1—Signaling Pathways—TP53—gallbladder cancer	1.96e-05	3.02e-05	CbGpPWpGaD
Crizotinib—PTK2B—Signaling Pathways—HRAS—gallbladder cancer	1.96e-05	3.02e-05	CbGpPWpGaD
Crizotinib—JAK2—Immune System—KRAS—gallbladder cancer	1.95e-05	3.01e-05	CbGpPWpGaD
Crizotinib—PTK2—Signaling Pathways—EGFR—gallbladder cancer	1.94e-05	2.99e-05	CbGpPWpGaD
Crizotinib—TYK2—Signaling Pathways—NRAS—gallbladder cancer	1.94e-05	2.98e-05	CbGpPWpGaD
Crizotinib—JAK2—Signaling Pathways—ERBB2—gallbladder cancer	1.93e-05	2.97e-05	CbGpPWpGaD
Crizotinib—YES1—Signaling Pathways—EGFR—gallbladder cancer	1.92e-05	2.95e-05	CbGpPWpGaD
Crizotinib—JAK2—Disease—EGFR—gallbladder cancer	1.91e-05	2.94e-05	CbGpPWpGaD
Crizotinib—RPS6KB1—Signaling Pathways—TP53—gallbladder cancer	1.9e-05	2.93e-05	CbGpPWpGaD
Crizotinib—NTRK1—Signaling Pathways—HRAS—gallbladder cancer	1.88e-05	2.89e-05	CbGpPWpGaD
Crizotinib—LCK—Disease—NRAS—gallbladder cancer	1.84e-05	2.82e-05	CbGpPWpGaD
Crizotinib—PTK2—Signaling Pathways—KRAS—gallbladder cancer	1.84e-05	2.82e-05	CbGpPWpGaD
Crizotinib—RPS6KB1—Signaling Pathways—HRAS—gallbladder cancer	1.82e-05	2.8e-05	CbGpPWpGaD
Crizotinib—JAK2—Signaling by GPCR—HRAS—gallbladder cancer	1.82e-05	2.8e-05	CbGpPWpGaD
Crizotinib—IRAK1—Signaling Pathways—EGFR—gallbladder cancer	1.82e-05	2.8e-05	CbGpPWpGaD
Crizotinib—LCK—Immune System—EGFR—gallbladder cancer	1.81e-05	2.79e-05	CbGpPWpGaD
Crizotinib—YES1—Signaling Pathways—KRAS—gallbladder cancer	1.81e-05	2.79e-05	CbGpPWpGaD
Crizotinib—JAK2—Disease—KRAS—gallbladder cancer	1.8e-05	2.78e-05	CbGpPWpGaD
Crizotinib—LYN—Immune System—HRAS—gallbladder cancer	1.78e-05	2.73e-05	CbGpPWpGaD
Crizotinib—ABL1—Immune System—HRAS—gallbladder cancer	1.77e-05	2.72e-05	CbGpPWpGaD
Crizotinib—TYK2—Signaling Pathways—EGFR—gallbladder cancer	1.77e-05	2.72e-05	CbGpPWpGaD
Crizotinib—SRC—Immune System—NRAS—gallbladder cancer	1.76e-05	2.71e-05	CbGpPWpGaD
Crizotinib—IRAK1—Signaling Pathways—KRAS—gallbladder cancer	1.72e-05	2.64e-05	CbGpPWpGaD
Crizotinib—LCK—Immune System—KRAS—gallbladder cancer	1.71e-05	2.63e-05	CbGpPWpGaD
Crizotinib—LCK—Signaling Pathways—ERBB2—gallbladder cancer	1.69e-05	2.6e-05	CbGpPWpGaD
Crizotinib—LCK—Disease—EGFR—gallbladder cancer	1.67e-05	2.57e-05	CbGpPWpGaD
Crizotinib—TYK2—Signaling Pathways—KRAS—gallbladder cancer	1.67e-05	2.57e-05	CbGpPWpGaD
Crizotinib—JAK2—Immune System—HRAS—gallbladder cancer	1.66e-05	2.56e-05	CbGpPWpGaD
Crizotinib—PTK2—Signaling Pathways—TP53—gallbladder cancer	1.63e-05	2.51e-05	CbGpPWpGaD
Crizotinib—SRC—Disease—NRAS—gallbladder cancer	1.63e-05	2.5e-05	CbGpPWpGaD
Crizotinib—YES1—Signaling Pathways—TP53—gallbladder cancer	1.61e-05	2.48e-05	CbGpPWpGaD
Crizotinib—SRC—Immune System—EGFR—gallbladder cancer	1.6e-05	2.47e-05	CbGpPWpGaD
Crizotinib—LCK—Disease—KRAS—gallbladder cancer	1.58e-05	2.43e-05	CbGpPWpGaD
Crizotinib—LYN—Signaling Pathways—NRAS—gallbladder cancer	1.57e-05	2.41e-05	CbGpPWpGaD
Crizotinib—PTK2—Signaling Pathways—HRAS—gallbladder cancer	1.56e-05	2.4e-05	CbGpPWpGaD
Crizotinib—YES1—Signaling Pathways—HRAS—gallbladder cancer	1.54e-05	2.37e-05	CbGpPWpGaD
Crizotinib—JAK2—Disease—HRAS—gallbladder cancer	1.53e-05	2.36e-05	CbGpPWpGaD
Crizotinib—IRAK1—Signaling Pathways—TP53—gallbladder cancer	1.53e-05	2.35e-05	CbGpPWpGaD
Crizotinib—SRC—Immune System—KRAS—gallbladder cancer	1.52e-05	2.33e-05	CbGpPWpGaD
Crizotinib—SRC—Signaling Pathways—ERBB2—gallbladder cancer	1.5e-05	2.3e-05	CbGpPWpGaD
Crizotinib—TYK2—Signaling Pathways—TP53—gallbladder cancer	1.48e-05	2.28e-05	CbGpPWpGaD
Crizotinib—SRC—Disease—EGFR—gallbladder cancer	1.48e-05	2.28e-05	CbGpPWpGaD
Crizotinib—JAK2—Signaling Pathways—NRAS—gallbladder cancer	1.47e-05	2.26e-05	CbGpPWpGaD
Crizotinib—IRAK1—Signaling Pathways—HRAS—gallbladder cancer	1.46e-05	2.25e-05	CbGpPWpGaD
Crizotinib—LCK—Immune System—HRAS—gallbladder cancer	1.46e-05	2.24e-05	CbGpPWpGaD
Crizotinib—LYN—Signaling Pathways—EGFR—gallbladder cancer	1.43e-05	2.2e-05	CbGpPWpGaD
Crizotinib—TYK2—Signaling Pathways—HRAS—gallbladder cancer	1.42e-05	2.18e-05	CbGpPWpGaD
Crizotinib—SRC—Disease—KRAS—gallbladder cancer	1.4e-05	2.15e-05	CbGpPWpGaD
Crizotinib—LYN—Signaling Pathways—KRAS—gallbladder cancer	1.35e-05	2.08e-05	CbGpPWpGaD
Crizotinib—LCK—Disease—HRAS—gallbladder cancer	1.34e-05	2.07e-05	CbGpPWpGaD
Crizotinib—JAK2—Signaling Pathways—EGFR—gallbladder cancer	1.34e-05	2.06e-05	CbGpPWpGaD
Crizotinib—SRC—Immune System—HRAS—gallbladder cancer	1.29e-05	1.98e-05	CbGpPWpGaD
Crizotinib—LCK—Signaling Pathways—NRAS—gallbladder cancer	1.29e-05	1.98e-05	CbGpPWpGaD
Crizotinib—JAK2—Signaling Pathways—KRAS—gallbladder cancer	1.26e-05	1.94e-05	CbGpPWpGaD
Crizotinib—LYN—Signaling Pathways—TP53—gallbladder cancer	1.2e-05	1.85e-05	CbGpPWpGaD
Crizotinib—SRC—Disease—HRAS—gallbladder cancer	1.19e-05	1.83e-05	CbGpPWpGaD
Crizotinib—LCK—Signaling Pathways—EGFR—gallbladder cancer	1.17e-05	1.8e-05	CbGpPWpGaD
Crizotinib—LYN—Signaling Pathways—HRAS—gallbladder cancer	1.15e-05	1.77e-05	CbGpPWpGaD
Crizotinib—SRC—Signaling Pathways—NRAS—gallbladder cancer	1.14e-05	1.75e-05	CbGpPWpGaD
Crizotinib—JAK2—Signaling Pathways—TP53—gallbladder cancer	1.12e-05	1.73e-05	CbGpPWpGaD
Crizotinib—LCK—Signaling Pathways—KRAS—gallbladder cancer	1.11e-05	1.7e-05	CbGpPWpGaD
Crizotinib—JAK2—Signaling Pathways—HRAS—gallbladder cancer	1.07e-05	1.65e-05	CbGpPWpGaD
Crizotinib—SRC—Signaling Pathways—EGFR—gallbladder cancer	1.04e-05	1.6e-05	CbGpPWpGaD
Crizotinib—LCK—Signaling Pathways—TP53—gallbladder cancer	9.84e-06	1.51e-05	CbGpPWpGaD
Crizotinib—SRC—Signaling Pathways—KRAS—gallbladder cancer	9.8e-06	1.51e-05	CbGpPWpGaD
Crizotinib—LCK—Signaling Pathways—HRAS—gallbladder cancer	9.41e-06	1.45e-05	CbGpPWpGaD
Crizotinib—SRC—Signaling Pathways—TP53—gallbladder cancer	8.71e-06	1.34e-05	CbGpPWpGaD
Crizotinib—SRC—Signaling Pathways—HRAS—gallbladder cancer	8.33e-06	1.28e-05	CbGpPWpGaD
